Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
Our Class A common stock began trading on the NYSE under the symbol “DNA” on September 17, 2021. Prior to that date, there was no public trading market for our Class A common stock.
Holders of Record
As of December 31, 2025, there were approximately 421 stockholders of record of our Class A common stock, 104 stockholders of record of our Class B common stock and 1 stockholder of record of our Class C common stock, which does not include persons whose stock is held in nominee or “street name” accounts through brokers, banks and intermediaries.
Securities Authorized for Issuance Under Equity Compensation Plans
Number of securities to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units (#) Weighted-average exercise price of outstanding options ($) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in the first column) (#)
Equity compensation plans approved by security holders (1) 6,002,588 (2) $ 151.78 3,336,606 (3)
Equity compensation plans not approved by security holders (4) 34,119 — 292,172
Total 6,036,707 $ 151.78 3,628,778
(1) Includes the Ginkgo Bioworks Holdings, Inc. 2021 Equity Incentive Plan.
(2) Includes 366,567 shares of common stock issuable upon the exercise of outstanding stock options and 5,636,021 shares of common stock issuable upon settlement of outstanding restricted stock units.
(3) The Plan provides that the number of shares of common stock reserved and available for issuance under the Plan shall be cumulatively increased on January 1 of each year. The number of shares of common stock increased each year will be equal to the lesser of: (i) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser amount as determined by our board of directors.
(4) Includes the Ginkgo Bioworks Holdings, Inc. 2022 Inducement Plan.
Performance Graph
The following graph compares the cumulative total stockholder return on our Class A common stock relative to the cumulative total returns of the S&P 500 Index and the S&P Biotechnology Select Industry Index between September 17, 2021 (the date our common stock began trading on the NYSE after the SRNG Business Combination) through December 31, 2025. All values assume a $100 initial investment at market close on September 17, 2021 and data for the S&P 500 and the S&P Biotechnology Select indices assume reinvestment of all dividends.
63
Table of Contents
Recent Sales of Unregistered Securities
On May 9, 2025, in a private placement transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act, we issued a total of 102,922 shares of our Class A common stock to StrideBio, Inc., valued at approximately $0.8 million, in settlement of the purchase price holdback amount payable in connection with Ginkgo’s acquisition of certain assets from StrideBio in 2023.
Issuer Purchases of Equity Securities
None.
Item 6. [Reserved]